Bibliography
- Wald A, Scarpignato C, Mueller-Lissner S, et al. A multinational survey of revalence and patterns of laxative use among adults with self-defined constipation. Aliment Pharmacol Ther 2008;28:917-30
- Suares NC, Ford AC. Prevalence of, and risk factors for, chronic idiopathic constipation in the community: systematic review and meta-analysis. Am J Gastroenterol 2011;106:1582-91
- Talley NJ. Functional gastrointestinal disorders as a public health problem. Neurogastroenterol Motil 2008;20:121-9
- Sanchez MI, Bercik P. Epidemiology and burden of chronic constipation. Can J Gastroenterol 2011;25:11-15
- Chang JY, Locke GR III, McNally MA, et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol 2010;105:822-32
- Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91
- Andrews CN, Storr M. The pathophysiology of chronic constipation. Can J Gastroenterol 2011;25:16-21
- Atkinson W, Lockhart S, Whorwell PJ, et al. Altered 5-hydroxytryptamine signaling in patients with constipation and diarrhea-predominant irritable bowel syndrome. Gastroenterology 2006;130:34-43
- Tack J, Camilleri M, Chang L, et al. Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders. Aliment Pharmacol Ther 2012;35:745-67
- Shin A, Camilleri M, Kolar G, et al. Systematic review with meta-analysis: highly selective 5-HT4 agonists (prucalopride, velusetrag or naronapride) in chronic constipation. Aliment Pharmacol Ther 2014;39:239-53
- Tack J, Corsetti M. Prucalopride: evaluation of the pharmacokinetics, pharmacodynamics, efficacy and safety in the treatment of chronic constipation. Expert Opin Drug Metab Toxicol 2012;8:1327-35
- Chamberlain SM, Rao SS. Safety evaluation of lubiprostone in the treatment of constipation and irritable bowel syndrome. Expert Opin Drug Saf 2012;11:841-50
- Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci 2010;55:1090-7
- Lembo AJ, Johanson JF, Parkman HP, et al. Long-term safety and effectiveness of lubiprostone, a chloride channel (ClC-2) activator, in patients with chronic idiopathic constipation. Dig Dis Sci 2011;56:2639-45
- Mozaffari S, Nikfar S, Abdollahi M. The safety of novel drugs used to treat irritable bowel syndrome. Expert Opin Drug Saf 2014. [ Epub ahead of print]
- Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology 2010;138:886-95
- Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther 2007;25:599-608
- Camilleri M, Vazquez-Roque MI, Burton D, et al. Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans. Neurogastroenterol Motil 2007;19:30-8
- Palme M, Milner PG, Ellis DJ, et al. A novel gastrointestinal prokinetic, ATI-7505, increased spontaneous bowel movements (Sbms) in a phase II, randomized, placebo-controlled study of patients with chronic idiopathic constipation (CIC). Gastroenterology 2010;138:S128-9
- Smith JA, Beattie DT, Marquess D, et al. The in vitro pharmacological profile of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378:125-37
- Beattie DT, Higgins DL, Ero MP, et al. An in vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954. Vascul Pharmacol 2013;58:150-6
- Beattie DT, Armstrong SR, Shaw JP, et al. The in vivo gastrointestinal activity of TD-5108, a selective 5-HT(4) receptor agonist with high intrinsic activity. Naunyn Schmiedebergs Arch Pharmacol 2008;378:139-47
- Shaw J-P, Beattie D, Cheong S-K, et al. Preclinical Pharmacokinetics of TD-5108, a selective, high intrinsic activity and orally bioavailable 5-HT4 receptor agonist. AAPS Ann Meet Expos. Presented at the annual meeting of the American Association of Pharmaceutical Scientists 2007;9:2422
- Wong SL, Goldberg MR, Shaw J, et al. In healthy subjects, TD-5108, a selective high intrinsic activity 5-HT4 receptor agonist, shows dose-proportional pharmacokinetics and exhibits a profile consistent with once-daily dosing. Gastroenterology 2007;132:A374
- Goldberg MR, Wong SL, Ganju J, et al. TD-5108, a selective 5- HT4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects. Gastroenterology 2007;132:A60
- Manini ML, Camilleri M, Goldberg M, et al. Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation. Neurogastroenterol Motil 2010;22:42-9
- Goldberg M, Li YP, Johanson JF, et al. Clinical trial: the efficacy and tolerability of velusetrag, a selective 5-HT4 agonist with high intrinsic activity, in chronic idiopathic constipation - a 4-week, randomized, double-blind, placebo-controlled, dose-response study. Aliment Pharmacol Ther 2010;32:1102-12
- SK biopharmaceuticals company. YKP10811 (chronic constipations). BIO_USA-Poster_11_YKP_1081 Available from: http://www.skbp.com and http://ri.search.yahoo.com/_ylt=A0LEVybUCEBTXiYAEAVXNyoA;_ylu=X3oDMTEzdjhiYXRpBHNlYwNzcgRwb3MDMQRjb2xvA2JmMQR2dGlkA1ZJUDM1N18x/RV=2/RE=1396734294/RO=10/RU=http%3a%2f%2fwww.kddf.org%2fcommon%2ffile%2f%3fidx%3d1416%26fname%3dBIO_USA-Poster_11_YKP_1081.pdf/RK=0/RS=ek2s9h08t6PaljYgSaTeaA85GWM-
- SK Chemicals Co.,Ltd. Efficacy and safety of ykp10811 in subjects with irritable bowel syndrome with constipation. 2014. Available from: http://www.clinicaltrial.gov/ct2/show/NCT02082457?term=NCT02082457&rank=1
- SK Life Science. A Phase 2 study to evaluate pharmacodynamics of ykp10811 in patients with chronic or functional constipation. 2012. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01523184?term=NCT01523184&rank=1
- SK Life Science. A multicenter, double-blind, randomized, placebo-controlled, 12-week, dose-range-finding trial of ykp10811 capsules administered once daily to subjects with chronic idiopathic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01989234?term=NCT01989234&rank=1
- Beattie DT, Armstrong SR, Vickery RG, et al. The pharmacology of TD-8954, a potent and selective 5-ht(4) receptor agonist with gastrointestinal prokinetic properties. Front Pharmacol 2011;2:25
- Beattie DT, Vickery RG, Arm-strong SR, et al. TD-8954 is a highly potent and selective 5-HT4 receptor agonist with potential utility in disorders of reduced gastrointestinal motility. Gastroenterology 2008;134:A-247
- Theravance, Inc. A Phase 1, multiple intravenous dose study to examine the safety, tolerability, and pharmacokinetics of intravenous TD-8954, a 5-HT4 receptor agonist, in healthy subjects. 2012. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01644240?term=NCT01644240&rank=1
- Simrén M, Bajor A, Gillberg PG, et al. Randomised clinical trial: the ileal bile acid transporter inhibitor A3309 vs. placebo in patients with chronic idiopathic constipation – a double-blind study. Aliment Pharmacol Ther 2011;34:41-50
- Chey WD, Camilleri M, Chang L, et al. A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation. Am J Gastroenterol 2011;106:1803-12
- Wong BS, Camilleri M, McKinzie S, et al. Effects of A3309, an ileal bile acid transporter inhibitor, on colonic transit and symptoms in females with functional constipation. Am J Gastroenterol 2011;106:2154-64
- Ferring Pharmaceuticals. 12 Week efficacy and safety trial followed by a 4 week withdrawal period for patients with chronic idiopathic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01833065?term=NCT01833065&rank=1
- Ferring Pharmaceuticals. 26 Week efficacy and safety trial for patients with chronic idiopathic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/record/NCT01827592?term=NCT01827592&rank=1
- Albireo. Study of A3309 in patients with chronic idiopathic constipation. 2009. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01007123?term=NCT01007123&rank=1
- Mayo Clinic. Effect of ileal bile acid transporter inhibitor in functional constipation. 2009. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01038687?term=NCT01038687&rank=1
- Ferring Pharmaceuticals. Safety and tolerability extension trial for patients with chronic idiopathic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01895543?term=NCT01895543&rank=1
- Kissei Pharmaceutical Co., Ltd. A single-blind, dose-tapering study of KWA-0711 in patients with chronic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/record/NCT01937663?term=NCT01937663&rank=1
- Kissei Pharmaceutical Co., Ltd. A single-blind, dose-titration study of KWA-0711 in patients with chronic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/record/NCT01938196?term=NCT01938196&rank=1
- Kissei Pharmaceutical Co., Ltd. A exploratory study of kwa-0711 in patients with chronic idiopathic constipation (CIC). 2012. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01600001?term=NCT01600001&rank=1
- Charoenthongtrakul S, Giuliana D, Longo KA, et al. Enhanced gastrointestinal motility with orally active ghrelin receptor agonists. J Pharmacol Exp Ther 2009;329:1178-86
- Shimizu Y, Chang EC, Shafton AD, et al. Evidence that stimulation of ghrelin receptors in the spinal cord initiates propulsive activity in the colon of the rat. J Physiol 2006;576:329-38
- Shin A, Camilleri M, Busciglio I, et al. Randomized controlled phase Ib study of ghrelin agonist, RM-131, in type 2 diabetic women with delayed gastric emptying: pharmacokinetics and pharmacodynamics. Diabetes Care 2013;36:41-8
- Rhythm Pharmaceuticals, Inc. A Phase 2 study to evaluate the safety and efficacy of rm-131 in patients with parkinson’s disease & chronic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/record/NCT01955616?term=NCT01955616&rank=1
- Rhythm Pharmaceuticals, Inc. Phase 2 study to evaluate safety and efficacy of rm-131 administered to patients with chronic constipation. 2013. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01781104?term=NCT01781104&rank=1
- Iwanaga Y, Miyashita N, Saito T, et al. Gastroprokinetic effect of a new benzamide derivative itopride and its action mechanisms in conscious dogs. Jpn J Pharmacol 1996;71:129-37
- Huang X, Lv B, Zhang S, et al. Itopride therapy for functional dyspepsia: a meta-analysis. World J Gastroenterol 2012;18:7371-7
- Lim HC, Kim YG, Lim JH, et al. Effect of itopride hydrochloride on the ileal and colonic motility in guinea pig in vitro. Yonsei Med J 2008;49:472-8
- Tsubouchi T, Saito T, Mizutani F, et al. Stimulatory action of itopride hydrochloride on colonic motor activity in vitro and in vivo. J Pharmacol Exp Ther 2003;306:787-93
- Chiba T, Tokunaga Y, Ikeda K, et al. Effects of itopride hydrochloride and ranitidine in patients with functional dyspepsia: comparison between prokinetic and acid suppression therapies. Hepatogastroenterology 2007;54:1878-81
- Shanghai Jiao Tong University School of Medicine. Itopride as an adjuvant for bowel preparation in patients with chronic constipation is effective. 2012. Available from: http://www.clinicaltrial.gov/ct2/show/NCT01513811?term=NCT01513811&rank=1
- Ozaki K, Sudo H, Muramatsu H, et al. Mitemcinal (GM-611), an orally active motilin receptor agonist, accelerates colonic motility and bowel movement in conscious dogs. Inflammopharmacology 2007;15:36-42
- Sudo H, Ozaki K, Muramatsu H, et al. Mitemcinal (GM-611), an orally active motilin agonist, facilitates defecation in rabbits and dogs without causing loose stools. Neurogastroenterol Motil 2007;19:318-26
- Available from: https://pubchem.ncbi.nlm.nih.gov